Your browser doesn't support javascript.
loading
A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Blommestein, Hedwig M; Verelst, Silvia G R; de Groot, Saskia; Huijgens, Peter C; Sonneveld, Pieter; Uyl-de Groot, Carin A.
Affiliation
  • Blommestein HM; Department of Health Policy & Management/institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands.
  • Verelst SG; Comprehensive Cancer Organisation, Utrecht, The Netherlands.
  • de Groot S; Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Huijgens PC; Department of Health Policy & Management/institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands.
  • Sonneveld P; Comprehensive Cancer Organisation, Utrecht, The Netherlands.
  • Uyl-de Groot CA; VU Medical Center Amsterdam, Amsterdam, The Netherlands.
Eur J Haematol ; 96(2): 198-208, 2016 Feb.
Article in En | MEDLINE | ID: mdl-25892333

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Antineoplastic Combined Chemotherapy Protocols / Cost-Benefit Analysis / Bortezomib / Multiple Myeloma Type of study: Health_economic_evaluation / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2016 Type: Article Affiliation country: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Antineoplastic Combined Chemotherapy Protocols / Cost-Benefit Analysis / Bortezomib / Multiple Myeloma Type of study: Health_economic_evaluation / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2016 Type: Article Affiliation country: Netherlands